Meeting Banner
Abstract #1574

Prevalence of Nephrogenic Systemic Fibrosis (NSF) in Dialysis Patients: Final Results of the Pro-FINEST Study

Sabine Amet1, Vincent Launay-Vacher1, Gilbert Deray2, Aurore Tricotel3, Camille Francs4, Jean-Yves Gauvrit5, Nicolas Grenier6, Genevive Reinhardt7, Maurice Laville8, Nicolas Janus1, Laurence Rouillon1, Gabriel Choukroun9, Olivier Clment10

1Service ICAR, Nephrology department, Pitie-Salpetriere Hospital, Paris, France; 2Nephrology, Pitie-Salpetriere Hospital, Paris, France; 3Pharmacovigilance, ANSM, Saint-Denis Cedex, France; 4Dermatology, Tenon Hospital, Paris cedex 20, France; 5Radiology, Pontchaillou Hospital, Rennes cedex 09, France; 6Radiology, Pellegrin Hospital, Bordeaux, France; 7Radiology, Haguenau Hospital, Haguenau, France; 8Nephrology, Edouard Herriot Hospital, Lyon, France; 9Nephrology, South Hospital, Amiens, France; 10Radiology, European G. Pompidou Hospital, Paris cedex 15, France

Nephrogenic Systemic Fibrosis (NSF) is a cutaneous disorder characterized by widespread tissue fibrosis. Although the exact physiopathology is still unknown, emergence of NSF has been linked with gadolinium based contrast media (GBCA). The Pro-FINEST study was supported by the French societies of dermatology, nephrology and radiology, and the university seminars of nephrology. The study was sponsored by the French drug agency (ANSM) and the French society of radiology. It aims at determining the prevalence of NSF after a Magnetic Resonance Imaging (MRI) examination, with or without GBCA, in chronic dialysis patients.